THE Australian Competition & Consumer Commission (ACCC) will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands.
Bayer and Elanco are close to sealing to major deal covering a range of animal health products. Image Mark Saunders.
The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs.
Animal and non-animal proteins are expected to be in demand for the next decade.
